Search Result

Results for "

C18-Ceramide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) CXCR (2) Drug Intermediate (1) Endogenous Metabolite (5) Insulin Receptor (1) Isotope-Labeled Compounds (5) Melanocortin Receptor (1) Mitochondrial Metabolism (1) Mitophagy (1) Neuropeptide Y Receptor (2) Parasite (1) PINK1/Parkin (1) Reference Standards (1) Trk Receptor (1)
By Research Areas:	Cancer (6) Endocrinology (1) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (8)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100355

C18-Ceramide (d18:1/18:0) C18-Ceramide	Endogenous Metabolite	Neurological Disease Cancer
C18-Ceramide (d18:1/18:0) is a bioactive molecule with multiple functions in cells, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology .

HY-P4070

Insulin icodec	Insulin Receptor	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA_1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-100355S1

C18-Ceramide-d7	Isotope-Labeled Compounds Endogenous Metabolite	Others
C18-Ceramide-d₇ is deuterium labeled C18-Ceramide.

HY-100355R

C18-Ceramide (Standard)	Endogenous Metabolite Reference Standards	Neurological Disease Cancer
C18-Ceramide (Standard) is the analytical standard of C18-Ceramide. This product is intended for research and analytical applications. C18-Ceramide can promote exocytosis of glutamate from damaged neurons. C18-Ceramide promotes cell death in glioma cells. Ceramides is involved in diverse cellular functions, such as differentiation, cell cycle progression, cell-cell adhesion, senescence, and apoptosis .

HY-176568

LCL768	Mitophagy PINK1/Parkin Mitochondrial Metabolism	Neurological Disease Cancer
LCL768 is a ceramide analog. LCL768 attenuates PARKIN succination to promote PARKIN activation and mitophagy. LCL768 induces CerS1-mediated endogenous C18-ceramide accumulation in mitochondria to mediate mitophagy, which is dependent on DRP1 activation via nitrosylation at C644. LCL768 alters mitochondrial metabolism, resulting in fumarate depletion and leading to tumor suppression. LCL768 improves sensorimotor defects in neurodegenerative diseases like ALS .

HY-100355S

C18-Ceramide-d3	Isotope-Labeled Compounds	Others
C18-Ceramide-d₃ is the deuterium labeled C18-Ceramide .

HY-W654105

C18-Ceramide-13C2,d2	Isotope-Labeled Compounds	Others
C18-Ceramide-13C2,d2 is a deuterated labeled C18-Ceramide-13C2,d2 .

HY-W698686S

*β-Galactosyl-C18-ceramide-d35*	Isotope-Labeled Compounds Others	Others
β-Galactosyl-C18-ceramide-d₃5 is deuterium labeled β-Galactosyl-C18-ceramide. β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition .

HY-W698686

β-Galactosyl-C18-ceramide	Biochemical Assay Reagents
β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition.

HY-152021S

C18 Ceramide-1-phosphate (d18:1/18:0)-d3	Isotope-Labeled Compounds	Others
C18 Ceramide-1-phosphate (d18:1/18:0)-d₃ is the deuterium labeled C18 Ceramide-1-phosphate (d18:1/18:0) (HY-160850). C18 Ceramide-1-phosphate (d18:1/18:0) is a specific type of long-chain molecule found in murine skin. C18 Ceramide-1-phosphate (d18:1/18:0) promotes migration of both mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells at concentrations between 0.5-5 μM. C18 Ceramide-1-phosphate (d18:1/18:0)’s levels are higher in CFPAC-1 pancreatic ductal adenocarcinoma cells than in pancreatic cancer stem cells .

HY-160850

C18 Ceramide-1-phosphate (d18:1/18:0) ammonium salt	Endogenous Metabolite	Endocrinology
C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) is a specific type of long-chain molecule found in murine skin . C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) promotes migration of both mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells at concentrations between 0.5-5 µM. C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt)’s levels are higher in CFPAC-1 pancreatic ductal adenocarcinoma cells than in pancreatic cancer stem cells .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-172000

(S)-3-Keto sphinganine (d18:0) hydrochloride	Drug Intermediate	Neurological Disease
(S)-3-Keto sphinganine (d18:0) hydrochloride is an intermediate in the biosynthesis of C18-Ceramide (HY-100355).

HY-179826

C18 Ceramide (d17:1/18:0)	Others	Inflammation/Immunology
C18 Ceramide (d17:1/18:0) is a ceramide.

HY-158873

N,N-Dihexyl sphingosine (d18:1/6:0/6:0) N,N-Dihexyl-D-erythro-sphingosine	Endogenous Metabolite	Neurological Disease
N,N-Dihexyl sphingosine (d18:1/6:0/6:0) (N,N-Dihexyl-D-erythro-sphingosine) is a synthetic analog of C18-Ceramide (HY-100355).

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P11480

TrkA/NGF-IN-1	Trk Receptor	Neurological Disease
TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC₅₀: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .

Cat. No.	Product Name	Type

HY-W698686

β-Galactosyl-C18-ceramide	Biochemical Assay Reagents
β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition.

β-Galactosyl-C18-ceramide

Biochemical Assay Reagents

β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition.

Cat. No.	Product Name	Target	Research Area

HY-P4070

Insulin icodec	Insulin Receptor	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA_1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P11480

TrkA/NGF-IN-1	Trk Receptor	Neurological Disease
TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC₅₀: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-100355

C18-Ceramide (d18:1/18:0) C18-Ceramide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
C18-Ceramide (d18:1/18:0) is a bioactive molecule with multiple functions in cells, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology .

HY-100355R

C18-Ceramide (Standard)	Alkaloids Other Alkaloids Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
C18-Ceramide (Standard) is the analytical standard of C18-Ceramide. This product is intended for research and analytical applications. C18-Ceramide can promote exocytosis of glutamate from damaged neurons. C18-Ceramide promotes cell death in glioma cells. Ceramides is involved in diverse cellular functions, such as differentiation, cell cycle progression, cell-cell adhesion, senescence, and apoptosis .

Cat. No.	Product Name	Chemical Structure

HY-100355S1

C18-Ceramide-d7
C18-Ceramide-d₇ is deuterium labeled C18-Ceramide.

HY-100355S

C18-Ceramide-d3
C18-Ceramide-d₃ is the deuterium labeled C18-Ceramide .

HY-W654105

C18-Ceramide-13C2,d2
C18-Ceramide-13C2,d2 is a deuterated labeled C18-Ceramide-13C2,d2 .

HY-W698686S

*β-Galactosyl-C18-ceramide-d35*
β-Galactosyl-C18-ceramide-d₃5 is deuterium labeled β-Galactosyl-C18-ceramide. β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition .

β-Galactosyl-C18-ceramide-d35

β-Galactosyl-C18-ceramide-d₃5 is deuterium labeled β-Galactosyl-C18-ceramide. β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition .

HY-152021S

C18 Ceramide-1-phosphate (d18:1/18:0)-d3
C18 Ceramide-1-phosphate (d18:1/18:0)-d₃ is the deuterium labeled C18 Ceramide-1-phosphate (d18:1/18:0) (HY-160850). C18 Ceramide-1-phosphate (d18:1/18:0) is a specific type of long-chain molecule found in murine skin. C18 Ceramide-1-phosphate (d18:1/18:0) promotes migration of both mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells at concentrations between 0.5-5 μM. C18 Ceramide-1-phosphate (d18:1/18:0)’s levels are higher in CFPAC-1 pancreatic ductal adenocarcinoma cells than in pancreatic cancer stem cells .

C18 Ceramide-1-phosphate (d18:1/18:0)-d3

C18 Ceramide-1-phosphate (d18:1/18:0)-d₃ is the deuterium labeled C18 Ceramide-1-phosphate (d18:1/18:0) (HY-160850). C18 Ceramide-1-phosphate (d18:1/18:0) is a specific type of long-chain molecule found in murine skin. C18 Ceramide-1-phosphate (d18:1/18:0) promotes migration of both mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells at concentrations between 0.5-5 μM. C18 Ceramide-1-phosphate (d18:1/18:0)’s levels are higher in CFPAC-1 pancreatic ductal adenocarcinoma cells than in pancreatic cancer stem cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

C18-Ceramide

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products